DelveInsight’s, “Anal Cancer Pipeline Insight 2025” report provides comprehensive insights about 6+ companies and 8+ pipeline drugs in Anal Cancer pipeline landscape. It covers the Anal Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Anal Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Stay ahead with the latest insights! Download DelveInsight’s comprehensive Anal Cancer Pipeline Report to explore emerging therapies, key companies, and future treatment landscapes @ Anal Cancer Pipeline Outlook Report
Key Takeaways from the Anal Cancer Pipeline Report
- In July 2025, Incyte Corporation announced a Phase 3 global, multicenter, placebo-controlled double-blind randomized study that will enroll participants with inoperable locally recurrent or metastatic SCAC not previously treated with systemic chemotherapy.
- In July 2025, Merck Sharp & Dohme LLC conducted a study, participants with multiple types of advanced (unresectable and/or metastatic) solid tumors who have progressed on standard of care therapy will be treated with pembrolizumab (MK-3475).
- DelveInsight’s Anal Cancer pipeline report depicts a robust space with 6+ active players working to develop 8+ pipeline therapies for Anal Cancer treatment.
- The leading Anal Cancer Companies such as Incyte Corporation, Merck & Co., Novartis Pharmaceuticals, Advaxis and others.
- Promising Anal Cancer Pipeline Therapies such as VGX-3100, HPV-16 vaccine, Pembrolizumab, Paclitaxel, Carboplatin, MPDL3280A, Cisplatin, V503, Axalimogene filolisbac and others.
Discover how the Anal Cancer treatment paradigm is evolving. Access DelveInsight’s in-depth Anal Cancer Pipeline Analysis for a closer look at promising breakthroughs @ Anal Cancer Clinical Trials and Studies
Anal Cancer Emerging Drugs Profile
- PDS0101: Merck & Co
PDS0101 is a novel investigational human papillomavirus (HPV)-targeted immunotherapy that stimulates a potent targeted T cell attack against HPV-positive cancers. PDS0101 is given by a simple subcutaneous injection in combination with other immunotherapies and cancer treatments. Interim data suggests PDS0101 generates clinically effective immune responses, and the combination of PDS0101 with other treatments demonstrates significant disease control by shrinking tumors, delaying disease progression, and/or prolonging survival. The combination of PDS0101 with other treatments does not appear to compound the toxicity of other agents. Currently, the drug is being evaluated in the Phase II stage of its development for the treatment of patients with anal cancer.
- BMX-001: BioMimetix
BMX-001 is a metalloporphyrin, a novel class of redox-active, small molecule. The active center is designed to mimic the center of superoxide dismutase. The primary mechanism of action is modulation of cellular signaling pathways. BMX-001 inhibits both NFkB and HIF-1a. By inhibiting these pro-survival and pro-angiogenic transcription factors, BMX-001 augments tumor killing by radiation therapy and inhibits tumor regrowth. The inhibition of NFkB blocks major components of the inflammatory cascade which simultaneously results in protection of normal tissue from radiation induced injury. The drug is in phase I/II of clinical trials for the treatment of anal cancer.
The Anal Cancer Pipeline report provides insights into
- The report provides detailed insights about companies that are developing therapies for the treatment of Anal Cancer with aggregate therapies developed by each company for the same.
- It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Anal Cancer Treatment.
- Anal Cancer Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- Anal Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Anal Cancer market.
Get a detailed analysis of the latest innovations in the Anal Cancer pipeline. Explore DelveInsight’s expert-driven report today! @ Anal Cancer Unmet Needs
Anal Cancer Companies
Incyte Corporation, Merck & Co., Novartis Pharmaceuticals, Advaxis and others.
Anal Cancer Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Oral
- Intravenous
- Subcutaneous
- Parenteral
- Topical
Anal Cancer Products have been categorized under various Molecule types such as
- Recombinant fusion proteins
- Small molecule
- Monoclonal antibody
- Peptide
- Polymer
- Gene therapy
Download DelveInsight’s latest report to gain strategic insights into upcoming Anal Cancer Therapies and key Developments @ Anal Cancer Market Drivers and Barriers, and Future Perspectives
Scope of the Anal Cancer Pipeline Report
- Coverage- Global
- Anal Cancer Companies- Incyte Corporation, Merck & Co., Novartis Pharmaceuticals, Advaxis and others.
- Anal Cancer Pipeline Therapies- VGX-3100, HPV-16 vaccine, Pembrolizumab, Paclitaxel, Carboplatin, MPDL3280A, Cisplatin, V503, Axalimogene filolisbac and others.
- Anal Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
- Anal Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Which companies are leading the race in Anal Cancer drug development? Find out in DelveInsight’s exclusive Anal Cancer Pipeline Report—access it now! @ Anal Cancer Emerging Drugs and Major Companies
Table of Contents
- Introduction
- Executive Summary
- Anal Cancer: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Anal Cancer– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Retifanlimab: Incyte Corporation
- Mid Stage Products (Phase II)
- PDS0101: Merck & Co
- Early Stage Products (Phase I)
- Drug Name: Company Name
- Preclinical and Discovery Stage Products
- Drug name: Company name
- Inactive Products
- Anal Cancer Key Companies
- Anal Cancer Key Products
- Anal Cancer- Unmet Needs
- Anal Cancer- Market Drivers and Barriers
- Anal Cancer- Future Perspectives and Conclusion
- Anal Cancer Analyst Views
- Anal Cancer Key Companies
- Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/anal-cancer-pipeline-insight
